Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland. Soini, E., Asseburg, C., Taiha, M., Puolakka, K., Purcaru, O., & Luosujärvi, R. Advances in Therapy, 34(10):2316–2332, October, 2017. ![Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Methods: A probabilistic model with 12-week cycles and a societal approach was developed for the years 2015–2019, accounting for differences in ACR responses (meta-analysis), mortality, and persistence. The risk-sharing scheme included a treatment switch and refund of the costs associated with CZP acquisition if patients failed to achieve ACR20 response at week 12. For the current treatment mix, ACR20 at week 24 determined treatment continuation. Quality-adjusted life years were derived on the basis of the Health Utilities Index. Results: In the Finnish target population, CZP treatment with a risk-sharing scheme led to a estimated annual net expenditure decrease ranging from 1.7% in 2015 to 5.6% in 2019 compared with the current treatment mix. Per patient over the 5 years, CZP risk sharing was estimated to decrease the time without ACR response by 5%-units, decrease work absenteeism by 24 days, and increase the time with ACR20, ACR50, and ACR70 responses by 5%-, 6%-, and 1%-units, respectively, with a gain of 0.03 quality-adjusted life years. The modeled risk-sharing scheme showed reduced costs of €7866 per patient, with a more than 95% probability of cost-effectiveness when compared with the current treatment mix. Conclusion: The present analysis estimated that CZP, with or without the risk-sharing scheme, is a cost-effective alternative treatment
@article{soini_modeled_2017-1,
title = {Modeled {Health} {Economic} {Impact} of a {Hypothetical} {Certolizumab} {Pegol} {Risk}-{Sharing} {Scheme} for {Patients} with {Moderate}-to-{Severe} {Rheumatoid} {Arthritis} in {Finland}},
volume = {34},
issn = {0741-238X, 1865-8652},
url = {http://link.springer.com/10.1007/s12325-017-0614-8},
doi = {10.1007/s12325-017-0614-8},
abstract = {Methods: A probabilistic model with 12-week cycles and a societal approach was developed for the years 2015–2019, accounting for differences in ACR responses (meta-analysis), mortality, and persistence. The risk-sharing scheme included a treatment switch and refund of the costs associated with CZP acquisition if patients failed to achieve ACR20 response at week 12. For the current treatment mix, ACR20 at week 24 determined treatment continuation. Quality-adjusted life years were derived on the basis of the Health Utilities Index. Results: In the Finnish target population, CZP treatment with a risk-sharing scheme led to a estimated annual net expenditure decrease ranging from 1.7\% in 2015 to 5.6\% in 2019 compared with the current treatment mix. Per patient over the 5 years, CZP risk sharing was estimated to decrease the time without ACR response by 5\%-units, decrease work absenteeism by 24 days, and increase the time with ACR20, ACR50, and ACR70 responses by 5\%-, 6\%-, and 1\%-units, respectively, with a gain of 0.03 quality-adjusted life years. The modeled risk-sharing scheme showed reduced costs of €7866 per patient, with a more than 95\% probability of cost-effectiveness when compared with the current treatment mix. Conclusion: The present analysis estimated that CZP, with or without the risk-sharing scheme, is a cost-effective alternative treatment},
language = {en},
number = {10},
urldate = {2019-05-24},
journal = {Advances in Therapy},
author = {Soini, Erkki and Asseburg, Christian and Taiha, Maarit and Puolakka, Kari and Purcaru, Oana and Luosujärvi, Riitta},
month = oct,
year = {2017},
pages = {2316--2332},
file = {Soini et al. - 2017 - Modeled Health Economic Impact of a Hypothetical C.pdf:/Users/neil.hawkins/Zotero/storage/5XWD6M6P/Soini et al. - 2017 - Modeled Health Economic Impact of a Hypothetical C.pdf:application/pdf},
}
Downloads: 0
{"_id":"PQQ73Wz4EMzY8ZQtv","bibbaseid":"soini-asseburg-taiha-puolakka-purcaru-luosujrvi-modeledhealtheconomicimpactofahypotheticalcertolizumabpegolrisksharingschemeforpatientswithmoderatetosevererheumatoidarthritisinfinland-2017","author_short":["Soini, E.","Asseburg, C.","Taiha, M.","Puolakka, K.","Purcaru, O.","Luosujärvi, R."],"bibdata":{"bibtype":"article","type":"article","title":"Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland","volume":"34","issn":"0741-238X, 1865-8652","url":"http://link.springer.com/10.1007/s12325-017-0614-8","doi":"10.1007/s12325-017-0614-8","abstract":"Methods: A probabilistic model with 12-week cycles and a societal approach was developed for the years 2015–2019, accounting for differences in ACR responses (meta-analysis), mortality, and persistence. The risk-sharing scheme included a treatment switch and refund of the costs associated with CZP acquisition if patients failed to achieve ACR20 response at week 12. For the current treatment mix, ACR20 at week 24 determined treatment continuation. Quality-adjusted life years were derived on the basis of the Health Utilities Index. Results: In the Finnish target population, CZP treatment with a risk-sharing scheme led to a estimated annual net expenditure decrease ranging from 1.7% in 2015 to 5.6% in 2019 compared with the current treatment mix. Per patient over the 5 years, CZP risk sharing was estimated to decrease the time without ACR response by 5%-units, decrease work absenteeism by 24 days, and increase the time with ACR20, ACR50, and ACR70 responses by 5%-, 6%-, and 1%-units, respectively, with a gain of 0.03 quality-adjusted life years. The modeled risk-sharing scheme showed reduced costs of €7866 per patient, with a more than 95% probability of cost-effectiveness when compared with the current treatment mix. Conclusion: The present analysis estimated that CZP, with or without the risk-sharing scheme, is a cost-effective alternative treatment","language":"en","number":"10","urldate":"2019-05-24","journal":"Advances in Therapy","author":[{"propositions":[],"lastnames":["Soini"],"firstnames":["Erkki"],"suffixes":[]},{"propositions":[],"lastnames":["Asseburg"],"firstnames":["Christian"],"suffixes":[]},{"propositions":[],"lastnames":["Taiha"],"firstnames":["Maarit"],"suffixes":[]},{"propositions":[],"lastnames":["Puolakka"],"firstnames":["Kari"],"suffixes":[]},{"propositions":[],"lastnames":["Purcaru"],"firstnames":["Oana"],"suffixes":[]},{"propositions":[],"lastnames":["Luosujärvi"],"firstnames":["Riitta"],"suffixes":[]}],"month":"October","year":"2017","pages":"2316–2332","file":"Soini et al. - 2017 - Modeled Health Economic Impact of a Hypothetical C.pdf:/Users/neil.hawkins/Zotero/storage/5XWD6M6P/Soini et al. - 2017 - Modeled Health Economic Impact of a Hypothetical C.pdf:application/pdf","bibtex":"@article{soini_modeled_2017-1,\n\ttitle = {Modeled {Health} {Economic} {Impact} of a {Hypothetical} {Certolizumab} {Pegol} {Risk}-{Sharing} {Scheme} for {Patients} with {Moderate}-to-{Severe} {Rheumatoid} {Arthritis} in {Finland}},\n\tvolume = {34},\n\tissn = {0741-238X, 1865-8652},\n\turl = {http://link.springer.com/10.1007/s12325-017-0614-8},\n\tdoi = {10.1007/s12325-017-0614-8},\n\tabstract = {Methods: A probabilistic model with 12-week cycles and a societal approach was developed for the years 2015–2019, accounting for differences in ACR responses (meta-analysis), mortality, and persistence. The risk-sharing scheme included a treatment switch and refund of the costs associated with CZP acquisition if patients failed to achieve ACR20 response at week 12. For the current treatment mix, ACR20 at week 24 determined treatment continuation. Quality-adjusted life years were derived on the basis of the Health Utilities Index. Results: In the Finnish target population, CZP treatment with a risk-sharing scheme led to a estimated annual net expenditure decrease ranging from 1.7\\% in 2015 to 5.6\\% in 2019 compared with the current treatment mix. Per patient over the 5 years, CZP risk sharing was estimated to decrease the time without ACR response by 5\\%-units, decrease work absenteeism by 24 days, and increase the time with ACR20, ACR50, and ACR70 responses by 5\\%-, 6\\%-, and 1\\%-units, respectively, with a gain of 0.03 quality-adjusted life years. The modeled risk-sharing scheme showed reduced costs of €7866 per patient, with a more than 95\\% probability of cost-effectiveness when compared with the current treatment mix. Conclusion: The present analysis estimated that CZP, with or without the risk-sharing scheme, is a cost-effective alternative treatment},\n\tlanguage = {en},\n\tnumber = {10},\n\turldate = {2019-05-24},\n\tjournal = {Advances in Therapy},\n\tauthor = {Soini, Erkki and Asseburg, Christian and Taiha, Maarit and Puolakka, Kari and Purcaru, Oana and Luosujärvi, Riitta},\n\tmonth = oct,\n\tyear = {2017},\n\tpages = {2316--2332},\n\tfile = {Soini et al. - 2017 - Modeled Health Economic Impact of a Hypothetical C.pdf:/Users/neil.hawkins/Zotero/storage/5XWD6M6P/Soini et al. - 2017 - Modeled Health Economic Impact of a Hypothetical C.pdf:application/pdf},\n}\n\n","author_short":["Soini, E.","Asseburg, C.","Taiha, M.","Puolakka, K.","Purcaru, O.","Luosujärvi, R."],"bibbaseid":"soini-asseburg-taiha-puolakka-purcaru-luosujrvi-modeledhealtheconomicimpactofahypotheticalcertolizumabpegolrisksharingschemeforpatientswithmoderatetosevererheumatoidarthritisinfinland-2017","role":"author","urls":{"Paper":"http://link.springer.com/10.1007/s12325-017-0614-8"},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/f/FfNE7kWA6pCvwcJZF/myPubs.bib","dataSources":["ZaHtWavQhcwZqKLNF","iRRNaRs6FkffgErta","v8uQmZsBpiqycmskv"],"keywords":[],"search_terms":["modeled","health","economic","impact","hypothetical","certolizumab","pegol","risk","sharing","scheme","patients","moderate","severe","rheumatoid","arthritis","finland","soini","asseburg","taiha","puolakka","purcaru","luosujärvi"],"title":"Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland","year":2017}